Biotech Movers: Modular Medical Jumps, InnovAge Revenue Up 16%, Pyxis Data On Deck, Dogwood In Focus
Modular Medical (MODD) rose 13.48% in overnight trading after a 23.37% drop earlier, planning a 2026 launch for its Pivot tubeless patch pump. Jin Medical (ZJYL) gained 20.79% with no specific news. InnovAge (INNV) increased 9.51% after reporting a 15.9% revenue rise. Pyxis Oncology (PYXS) climbed 5% ahead of a key clinical update. Pulse Biosciences (PLSE) fell 2.48% despite clinical trial progress. Dermata (DRMA) rose 7.20% after launching its Tome skincare brand. Dogwood Therapeutics (DWTX) ga
How this was made
The 30-second read
Why it matters
Each company's specific news (earnings, trial updates, product launches) drives its individual price action, while the sector overall remains volatile.
Market read
Company‑specific news drives short‑term trading opportunities; broader market sentiment remains muted.
What to watch
Regulatory timelines for MICVO and Halneuron could delay value realization, and macro pressure from trade tensions may cap sector rally.
Background
The article provides a roundup of overnight price moves and recent corporate updates for several biotech companies amid broader market pressure from trade tensions and oil price concerns.
Ticker impact
InnovAge reported Q4 earnings with revenue up 15.9% YoY and a narrowed net loss, prompting a 9.5% after‑hours gain.
Potential upside of 5‑7% over the next few days if guidance holds.
Earnings beat and guidance raise expectations; market already reacted positively in after‑hours.
Pyxis Oncology announced a live webcast to present Phase 1 data for its lead candidate MICVO on Sep 9, 2026.
Possible 4‑6% move on the day of data release.
No data yet; market reaction depends on trial outcomes.
Pulse Biosciences posted Q2 2026 results showing a non‑GAAP net loss of $19.4 M and $0.4 M revenue, with progress on AF trials.
Potential 3‑5% decline in the short term.
Earnings miss combined with trial milestones creates mixed signals.
Dermata Therapeutics launched its Tome Foundational Treatment, its first commercial product, driving a 7% after‑hours rise.
Potential 2‑4% upside if sales traction materializes.
Launch is early stage; market reaction may be limited.
Dogwood Therapeutics reported Phase 2b enrollment for its pain candidate Halneuron and a 7% after‑hours gain.
Possible 3‑5% swing around the readout window.
No data yet; price movement driven by speculation.
Market effects
Biotech sector shows mixed signals with earnings beats and trial updates, indicating selective upside.
U.S. biotech stocks experienced varied after‑hours moves, reflecting company‑specific news rather than broader market trends.
Limited; news is confined to U.S. listed biotech firms.
Counterpoint
Despite earnings beats, high valuation multiples may limit upside; investors should watch cash burn.
Key entities
- CompanyInnovAge Holding Corp.
Provider of senior healthcare programs; reported Q4 earnings.
- CompanyPyxis Oncology
Biotech presenting Phase 1 data for MICVO.
- CompanyPulse Biosciences
Bioelectric medicine firm reporting Q2 results.
- CompanyDermata Therapeutics
Skincare company launching its first commercial product.
- CompanyDogwood Therapeutics
Biopharma advancing pain candidate Halneuron.
